172@29@17@242!~!172@29@0@53!~!|news|business|regeneron-pharmaceuticals-begins-covid-19-antibody-cocktail-late-stage-trial-5513691.html!~!|controller|infinite_scroll_article.php

Network18 Presents

partnered by

  • Galaxy Note20 | 20 Ultra
Moneycontrol
Financial Freedom Offer: Subscribe to Moneycontrol Pro and grab benefits worth ₹15,000/-

Network18 Presents

  • partnered by
  • Galaxy Note20 | 20 Ultra
you are here: HomeNewsBusiness
Last Updated : Jul 06, 2020 05:53 PM IST | Source: Reuters

Regeneron Pharmaceuticals begins COVID-19 antibody cocktail late-stage trial

The trial, run jointly with the National Institute of Allergy and Infectious Diseases (NIAID), would test the therapy's ability to prevent infection in those who have had close exposure to a COVID-19 patient.

Reuters
Representative image
Representative image

Regeneron Pharmaceuticals Inc said on Monday it began late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19, sending its shares up nearly 4 percent.

The trial, run jointly with the National Institute of Allergy and Infectious Diseases (NIAID), would test the therapy's ability to prevent infection in those who have had close exposure to a COVID-19 patient.

The late-stage trial, to be conducted across 100 sites and expected to enroll 2,000 patients in the US, begins after an assessment of the antibody cocktail's safety in an early-stage trial by an independent committee.

Close

"We are pleased to collaborate with NIAID to study REGN-COV2 in our quest to further prevent the spread of the virus with an anti-viral antibody cocktail that could be available much sooner than a vaccine," said Regeneron Chief Scientific Officer George Yancopoulos.

Shares of the drugmaker were up 3.6 percent at $645 in trading before the bell.

Follow our full coverage of the coronavirus pandemic here.
First Published on Jul 6, 2020 05:45 pm
Sections